About
At the 2023 United European Gastroenterology Week and the American College of Gastroenterology annual conferences, thousands of presentations showcasing the latest cutting-edge research in IBD were shared. Whether you couldn't attend the conferences or just need a recap of key IBD presentations, this webcast will review top-line highlights from pivotal IBD trials, summarizing the most clinically pertinent data.

Our Best of UEGW & ACG 2023 program was developed by an international group of IBD experts. Together, they reviewed all IBD-related clinical trials presented at the conferences to compile a condensed overview of the best and latest research. This in-depth summary, presented by Drs. Marla Dubinsky, David Rubin, and Elizabeth Spencer will provide valuable education to help you implement a new understanding of your ulcerative colitis and Crohn's disease practice.

Watch the streaming webinar now by completing the registration information.

Support for this activity has been made possible through educational grants from:
-Janssen Biotech, Inc. (administered by Janssen Scientific Affairs, LLC)
-Takeda Pharmaceuticals
Presenters
1708384027-5960d281a4d5e974
David T. Rubin, MD
Co-Founder, Cornerstones Health
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Director, Inflammatory Bowel Disease Center
The University of Chicago Medicine
Chicago, IL
1708384034-971578b107efbeee
Marla C. Dubinsky, MD
Co-Founder, Cornerstones Health
Co-Founder of Cornerstones Health
Professor of Pediatrics and Medicine
Chief, Pediatric Gastroenterology and Nutrition
Mount Sinai Kravis Children’s Hospital
Co-Director, Susan and Leonard Feinstein IBD Clinical Center
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Planning Clinic
Icahn School of Medicine, Mount Sinai
New York, NY
1708384041-896cff106bf2447c
Elizabeth Spencer, MD, MSc
Assistant Professor of Pediatric Gastroenterology
Mount Sinai Kravis Children’s Hospital
Icahn School of Medicine, Mount Sinai
New York, NY
Register To Watch Recording
Full name*
Email Address*
Title*
Organization*
State*
Country*
What is your profession?*
What is your specialty/area of focus?*
What is your practice setting?*
Approximately how many patients with IBD do you see in a week?*
How many years have you been in practice?*
Based on your current knowledge, in the Phase 3 QUASAR 12-week induction trial of guselkumab for moderate-to-severe UC, which statement is CORRECT? (dosed 200 mg IV for three doses)*
Based on your current knowledge, which statement is CORRECT regarding the pooled safety analysis of clinical trials of upadacitinib for maintenance of moderate-to-severe Crohn’s disease and ulcerative colitis?*
Based on your current knowledge, what were the results of the POWER study of re-induction with an additional dose of ustekinumab IV compared with continuing maintenance injections for patients with Crohn’s disease who were losing response?*
Based on your current knowledge, which statement is CORRECT regarding the EVOLVE study of complex Crohn's disease and treatment with ustekinumab or vedolizumab?*
How would you rate your confidence in implementing results of recently presented data about therapeutic options to improve the care of patients with IBD?*
How would you rate your confidence in discussing the risks and benefits of emerging therapeutic options with patients with IBD?*
How would you rate your confidence regarding incorporating the latest guidance on disease and drug monitoring into patient care?*
How would you rate your current knowledge regarding the latest data on disease-related outcomes for patients with IBD?*
How would you rate your current knowledge regarding the results of recent Phase 2 and Phase 3 IBD clinical trials?*
How would you rate your current knowledge regarding results of recent head-to-head studies in IBD?*
Did you attend the UEGW 2023 or ACG 2023 conference in person?*
Attended ACG 2023
Attended UEGW 2023
Neither
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.